ANSWER: B

Rationale:

Glutamate is the principal excitatory neurotransmitter in the CNS and is the endogenous agonist at the NMDA receptor, which is the molecular target that ketamine and esketamine block to produce their antidepressant effects. Glutamate operates through multiple receptor families including ionotropic receptors (NMDA, AMPA, and kainate receptors) and metabotropic glutamate receptors. The NMDA receptor is a ligand-gated ion channel that requires glutamate binding at its primary agonist site, along with co-agonist binding and membrane depolarization, for full activation. Ketamine enters the open NMDA channel pore and blocks ion conductance, making it an open-channel blocker of the glutamate system. This glutamatergic mechanism is fundamentally distinct from the monoamine-based mechanisms of all previously approved antidepressants.

• Option A: Option A is incorrect because GABA is the principal inhibitory neurotransmitter in the CNS, not the principal excitatory neurotransmitter. While GABAergic interneurons play a critical role in ketamine's mechanism of action (ketamine blocks NMDA receptors on these interneurons, producing disinhibition), GABA is not the endogenous agonist at the receptor ketamine blocks.
• Option C: Option C is incorrect because Dopamine is a catecholamine neurotransmitter involved in reward and motor circuits, but it is not the principal excitatory neurotransmitter in the CNS and is not the endogenous agonist at the NMDA receptor. Dopaminergic pathways are affected downstream by ketamine's actions but are not the direct target.
• Option D: Option D is incorrect because Serotonin is a monoamine neurotransmitter that is the target of SSRIs and SNRIs, but it is not the principal excitatory neurotransmitter and is not the endogenous agonist at the NMDA receptor. Ketamine's mechanism is explicitly non-serotonergic.
• Option E: Option E is incorrect because Acetylcholine is a neurotransmitter important in neuromuscular and autonomic function, but it is not the principal excitatory neurotransmitter in the CNS and does not act at the NMDA receptor.

ANSWER: D

Rationale:

The NMDA receptor has a unique activation requirement among ligand-gated ion channels: it is both voltage-dependent and ligand-dependent, requiring three simultaneous conditions for full channel opening. First, sufficient membrane depolarization must relieve the voltage-dependent Mg2+ block that occludes the channel pore at resting membrane potential. Second, glutamate must bind at the primary agonist site on the GluN2 subunit. Third, a co-agonist, either glycine or D-serine, must bind at the co-agonist site on the GluN1 subunit. Only when all three conditions are met does the channel conduct sodium, potassium, and calcium ions, with calcium influx being the primary signaling event for downstream synaptic plasticity and neuroplasticity. This triple-gating requirement distinguishes the NMDA receptor from other glutamate receptors such as AMPA receptors, which open with glutamate binding alone and do not require co-agonist binding or voltage-dependent relief of a channel block.

• Option A: Option A is incorrect because This is incorrect because glutamate binding alone is insufficient for NMDA receptor activation. Unlike AMPA receptors, which can be activated by glutamate alone, the NMDA receptor requires both glutamate and a co-agonist (glycine or D-serine) for channel opening, in addition to membrane depolarization.
• Option B: Option B is incorrect because This is incorrect because glycine is a co-agonist, not the primary agonist. Glycine binding alone does not open the NMDA channel. Both glutamate at the primary site and glycine or D-serine at the co-agonist site are required simultaneously.
• Option C: Option C is incorrect because This is incorrect because dopamine does not bind to the NMDA receptor. The co-agonist site on the NMDA receptor binds glycine or D-serine, not dopamine. While dopaminergic systems interact with glutamatergic circuits at a network level, dopamine is not a ligand at the NMDA receptor itself.
• Option E: Option E is incorrect because This is incorrect because GABA does not bind to the NMDA receptor. GABA acts at its own receptor families (GABA-A ionotropic and GABA-B metabotropic receptors). The co-agonist site on the NMDA receptor binds glycine or D-serine, not GABA.

ANSWER: A

Rationale:

Ketamine is an open-channel blocker of the NMDA receptor, meaning it can only enter and bind within the ion channel pore when the channel is in its open conformation following activation by glutamate and glycine or D-serine. This mechanism is classified as uncompetitive antagonism because the drug requires prior agonist-induced channel opening to access its binding site inside the pore. Once bound, ketamine blocks ion conductance through the channel. A defining feature of uncompetitive antagonism is that it cannot be overcome by increasing agonist concentration; adding more glutamate opens more channels, which paradoxically provides more binding sites for ketamine, potentially increasing rather than decreasing blockade. This distinguishes uncompetitive from competitive antagonism, where increasing agonist concentration can overcome the block. Ketamine's binding within the NMDA channel pore is use-dependent, meaning that channels with higher firing rates (more frequent opening) will experience greater blockade.

• Option B: Option B is incorrect because Competitive antagonism involves a drug competing with the endogenous agonist at the same binding site, with the block being surmountable by increasing agonist concentration. Ketamine does not compete with glutamate at the primary agonist site on the GluN2 subunit; instead, it binds within the channel pore after the channel has already been opened by agonist binding.
• Option C: Option C is incorrect because Noncompetitive allosteric antagonism involves binding to a site distinct from the agonist site and outside the channel pore, reducing receptor function through a conformational change. While both uncompetitive and noncompetitive antagonism are insurmountable by increased agonist, ketamine specifically binds inside the open channel pore (not at an allosteric site outside it), making uncompetitive the correct classification.
• Option D: Option D is incorrect because Inverse agonism involves a drug that binds to a constitutively active receptor and produces an effect opposite to that of the agonist, reducing receptor activity below baseline. This concept applies to receptors with constitutive activity such as certain GABA-A or histamine receptors, not to the mechanism by which ketamine blocks the NMDA channel pore.
• Option E: Option E is incorrect because Irreversible antagonism involves permanent covalent binding that inactivates the receptor until new receptor synthesis occurs. Ketamine's binding within the NMDA channel pore is reversible; the drug dissociates from the pore, and channel function is restored. Ketamine's half-life of two to three hours reflects this reversibility.

ANSWER: C

Rationale:

Esketamine, the S-enantiomer of ketamine, has approximately three to four times greater binding affinity for the NMDA receptor channel pore than arketamine, the R-enantiomer. This greater NMDA receptor affinity makes esketamine the more potent NMDA antagonist of the two enantiomers and also the more potent dissociative and psychotomimetic agent at equivalent doses. This pharmacological distinction is clinically relevant because esketamine is the enantiomer selected for the FDA-approved intranasal formulation (Spravato), where its greater potency at the NMDA receptor allows effective antidepressant dosing through the intranasal route despite the lower bioavailability of nasal compared with IV administration. Racemic IV ketamine contains both enantiomers in equal proportions, and its clinical effects represent the combined pharmacology of both.

• Option A: Option A is incorrect because This reverses the actual relationship. Esketamine (S-enantiomer), not arketamine (R-enantiomer), has the greater affinity for the NMDA receptor. Arketamine has lower NMDA affinity and is the less potent dissociative agent of the two.
• Option B: Option B is incorrect because The two enantiomers do not have identical NMDA receptor affinity. Esketamine has approximately three to four times greater affinity than arketamine, and they produce different degrees of dissociation at equivalent doses, with esketamine being the more potent dissociative agent.
• Option D: Option D is incorrect because The enantiomers do not have equal NMDA receptor affinity. Additionally, their pharmacokinetic half-lives are similar because both undergo hepatic metabolism via the same CYP enzymes (CYP3A4 and CYP2B6). The clinically important distinction is in receptor affinity and potency, not duration of action.
• Option E: Option E is incorrect because Both enantiomers have significant affinity for the NMDA receptor, and NMDA receptor blockade is the established primary mechanism of ketamine's antidepressant action. While opioid receptor interactions have been investigated as a contributing mechanism, stating that antidepressant effects are mediated entirely through opioid receptors is incorrect and contradicts the established evidence base.

ANSWER: E

Rationale:

Ketamine is classified as a Schedule III controlled substance under the United States Controlled Substances Act. This classification reflects its established potential for misuse and psychological dependence when used recreationally at higher doses and frequencies than those employed in clinical settings, balanced against its currently accepted medical uses in anesthesia and, more recently, its role in antidepressant treatment. Esketamine (the S-enantiomer marketed as Spravato) is also classified as Schedule III. At recreational doses, ketamine produces intense dissociation, euphoria, and amnestic effects that underlie its misuse as a club drug. The Schedule III classification carries legal consequences including prescribing restrictions and the requirement for DEA registration, and it informs the regulatory framework underlying the Risk Evaluation and Mitigation Strategy (REMS) program for esketamine.

• Option A: Option A is incorrect because Schedule I classification is reserved for substances with high abuse potential and no currently accepted medical use in the United States (such as heroin and MDMA in its non-approved context). Ketamine has well-established accepted medical uses in anesthesia and is used clinically for depression, making Schedule I incorrect.
• Option B: Option B is incorrect because Schedule II classification applies to substances with high abuse potential and currently accepted medical use but with severe dependence potential (such as morphine, fentanyl, and amphetamine). Ketamine's abuse potential, while real, is classified as moderate rather than high, placing it in Schedule III rather than Schedule II.
• Option C: Option C is incorrect because Schedule IV substances have lower abuse potential than Schedule III (examples include benzodiazepines and zolpidem). Ketamine's established recreational misuse profile and dependence potential place it at the Schedule III level, not Schedule IV.
• Option D: Option D is incorrect because Ketamine is a federally scheduled controlled substance. It requires a prescription from a licensed provider, and its dispensing is subject to DEA oversight. Stating that it is unscheduled and without prescribing restrictions is incorrect.

ANSWER: B

Rationale:

Esketamine (Spravato) is administered intranasally using a nasal spray device that delivers 28 mg per actuation. The approved doses are 56 mg (two actuations) or 84 mg (three actuations), with a five-minute interval between actuations on each nostril. This intranasal route was selected to provide a practical clinical alternative to IV infusion while maintaining rapid drug delivery to the systemic circulation through the nasal mucosa. The intranasal bioavailability of esketamine is approximately 48%, substantially lower than the 100% bioavailability of IV administration. Despite this lower bioavailability, the intranasal route enables a standardized, clinic-based administration protocol that does not require IV access or infusion equipment, making it more feasible for outpatient psychiatric settings than IV ketamine.

• Option A: Option A is incorrect because Intravenous infusion over 40 minutes describes the standard protocol for off-label IV racemic ketamine used in antidepressant treatment, not the FDA-approved esketamine formulation. Esketamine (Spravato) is specifically an intranasal product; there is no FDA-approved IV formulation of esketamine for depression.
• Option C: Option C is incorrect because Esketamine is not available as an oral tablet and cannot be self-administered at home. The REMS program for Spravato explicitly prohibits self-administration outside of a certified healthcare setting, and esketamine must be administered under clinical supervision with a minimum two-hour post-dose observation period.
• Option D: Option D is incorrect because Esketamine for depression is not administered by intramuscular injection. While ketamine can be given intramuscularly in anesthetic and emergency settings, the FDA-approved antidepressant formulation of esketamine is intranasal only.
• Option E: Option E is incorrect because There is no sublingual formulation of esketamine approved for depression. Sublingual delivery is used for some other psychiatric medications, but Spravato is formulated exclusively as a nasal spray.

ANSWER: D

Rationale:

The esketamine REMS program requires that every administration occur in a certified healthcare setting where patients are monitored for a minimum of two hours following each dose. Self-administration outside the clinical setting is explicitly prohibited under the REMS requirements. Patients must not drive or operate heavy machinery on the day of treatment, and a confirmed transportation plan must be in place before administration. The REMS program also mandates that esketamine be administered in conjunction with an oral antidepressant, not as monotherapy. These requirements apply to every administration throughout the treatment course, including both induction and maintenance phases. The REMS framework reflects the drug's dissociative and psychotomimetic effects, its potential for transient blood pressure elevation, and its Schedule III controlled substance status.

• Option A: Option A is incorrect because Self-administration at home is not permitted under the esketamine REMS at any point in the treatment course, regardless of how many supervised administrations have been completed. Every dose must be administered in a certified healthcare setting under direct clinical supervision.
• Option B: Option B is incorrect because The required post-dose observation period is a minimum of two hours, not 30 minutes. This duration reflects the time course of esketamine's dissociative and hemodynamic effects, which typically resolve within 60 to 90 minutes but require a full two-hour observation window for safety.
• Option C: Option C is incorrect because The REMS program mandates that esketamine must be used in conjunction with an oral antidepressant. Esketamine is not approved as monotherapy. The concurrent oral antidepressant is a required component of the treatment regimen under the FDA-approved labeling.
• Option E: Option E is incorrect because REMS requirements apply to all phases of treatment including both induction and maintenance. There is no point at which monitoring requirements are lifted or home administration becomes permitted.

ANSWER: C

Rationale:

The standard antidepressant dose of IV ketamine is 0.5 mg/kg infused over 40 minutes, a protocol established through the landmark clinical trials by Zarate and colleagues and subsequently adopted by most ketamine treatment centers. This dose is subanesthetic, meaning it is substantially below the 1 to 2 mg/kg IV bolus dose used for anesthesia induction. At 0.5 mg/kg over 40 minutes, patients experience transient dissociation, perceptual alterations, and mild hemodynamic changes including increases in heart rate and blood pressure, which typically resolve within 60 to 90 minutes after infusion completion. A single infusion at this dose produces antidepressant response in approximately 50% to 70% of patients with treatment-resistant depression, with onset within two to four hours and peak effect at 24 hours.

• Option A: Option A is incorrect because A dose of 2.0 mg/kg is at or above the anesthetic induction range and would produce surgical-depth anesthesia, not a subanesthetic antidepressant effect. This dose is not used for antidepressant treatment.
• Option B: Option B is incorrect because A dose of 0.1 mg/kg is substantially below the established antidepressant dose and has not been shown to produce consistent antidepressant effects. The 0.5 mg/kg dose was established because it provides sufficient NMDA receptor occupancy for the downstream cascade (glutamate burst, BDNF release, mTORC1 activation) while remaining subanesthetic.
• Option D: Option D is incorrect because A dose of 1.0 mg/kg approaches the anesthetic induction range and would produce effects well beyond the subanesthetic level intended for antidepressant use. The established antidepressant dose is 0.5 mg/kg, not 1.0 mg/kg.
• Option E: Option E is incorrect because While 0.5 mg/kg is the correct dose, it is infused over 40 minutes, not administered as a 2-minute bolus. A rapid bolus at this dose would produce more intense peak dissociative effects, greater hemodynamic instability, and a less favorable safety profile compared with the controlled 40-minute infusion protocol.

ANSWER: A

Rationale:

The FDA approval of esketamine in March 2019 represented the most significant regulatory advance in antidepressant pharmacology since the introduction of SSRIs because esketamine was the first approved antidepressant whose primary mechanism of action is non-monoaminergic. Every antidepressant approved before esketamine, including tricyclic antidepressants, MAO inhibitors, SSRIs, SNRIs, and atypical agents, acts primarily on monoamine systems (serotonin, norepinephrine, or dopamine). Esketamine's primary target is the NMDA glutamate receptor, making it the first approved antidepressant to work through the glutamatergic system. This approval validated the glutamatergic hypothesis of depression as a clinically actionable framework and opened a fundamentally new mechanistic pathway for antidepressant drug development.

• Option B: Option B is incorrect because Multiple antidepressants have been approved since the introduction of SSRIs in the 1980s, including venlafaxine, duloxetine, mirtazapine, bupropion, vilazodone, vortioxetine, and others. Esketamine's significance is not that it was the first antidepressant approved after SSRIs but that it was the first with a non-monoaminergic primary mechanism.
• Option C: Option C is incorrect because Esketamine is not approved as monotherapy. Under its FDA labeling and REMS program, esketamine must be administered in conjunction with an oral antidepressant. Monotherapy use is explicitly outside its approved indication.
• Option D: Option D is incorrect because While esketamine does produce rapid antidepressant effects, IV racemic ketamine had already been demonstrated in clinical trials to produce measurable effects within hours of administration before esketamine's approval. The significance of esketamine's approval is its non-monoaminergic mechanism and its regulatory status, not the speed of onset alone.
• Option E: Option E is incorrect because Multiple controlled substances have been approved for psychiatric indications before esketamine, including Schedule IV benzodiazepines for anxiety disorders and Schedule II stimulants such as amphetamine for attention-deficit/hyperactivity disorder. Esketamine's distinction is mechanistic, not related to its controlled substance status.

ANSWER: E

Rationale:

The temporal dissociation between ketamine's short pharmacokinetic half-life (two to three hours) and the duration of its antidepressant effect (three to seven days) is one of the most important observations in ketamine pharmacology. It demonstrates that direct NMDA receptor blockade is not itself the proximal antidepressant mechanism but rather the trigger for a cascade of downstream molecular events that produce lasting structural changes in synaptic architecture. This cascade begins with NMDA blockade on GABAergic interneurons, which produces a glutamate burst that activates AMPA receptors, stimulating the release of brain-derived neurotrophic factor (BDNF) and activation of tropomyosin receptor kinase B (TrkB). TrkB activation then drives the PI3K/Akt/mTORC1 signaling pathway, leading to rapid synthesis of synaptic proteins and new dendritic spine formation in prefrontal circuits. These structural synaptic changes, which occur within hours, persist well beyond ketamine's plasma clearance and represent the basis of the sustained antidepressant effect.

• Option A: Option A is incorrect because Ketamine does not bind irreversibly to the NMDA receptor. It is a reversible open-channel blocker that dissociates from the channel pore, with receptor occupancy declining as plasma concentrations fall during the drug's two-to-three-hour elimination half-life.
• Option B: Option B is incorrect because While ketamine is lipophilic and distributes into tissues including adipose, slow redistribution from fat does not account for a three-to-seven-day antidepressant effect. The plasma concentrations achieved through redistribution from adipose tissue are far below the threshold for meaningful NMDA receptor occupancy.
• Option C: Option C is incorrect because Norketamine does have a longer half-life than ketamine (approximately five hours, not five days), but this is still far shorter than the three-to-seven-day duration of antidepressant effect. Norketamine has weaker NMDA antagonist activity and does not account for the sustained clinical response on its own.
• Option D: Option D is incorrect because While ketamine's effects involve changes in gene expression related to synaptic protein synthesis, these are not permanent epigenetic modifications. The antidepressant effect is transient, typically waning over three to seven days without repeated dosing, which is inconsistent with permanent epigenetic changes.

ANSWER: B

Rationale:

The disinhibition model of ketamine's antidepressant mechanism begins with the preferential blockade of NMDA receptors located on tonically active GABAergic interneurons in the prefrontal cortex. Under normal conditions, these interneurons fire continuously and maintain inhibitory tone on glutamatergic pyramidal neurons, suppressing their output. When ketamine blocks NMDA receptors on these interneurons, their firing is suppressed, which releases pyramidal neurons from GABAergic inhibition. The resulting disinhibition produces a rapid, transient burst of glutamate release from the now-uninhibited pyramidal neurons. This glutamate burst activates postsynaptic AMPA receptors (which do not require voltage-dependent magnesium relief for activation), initiating the downstream cascade of BDNF release, TrkB activation, and mTORC1-dependent synaptogenesis that constitutes the structural basis of the antidepressant effect.

• Option A: Option A is incorrect because This reverses the actual mechanism. Ketamine does not directly silence pyramidal neurons. Instead, it blocks NMDA receptors on GABAergic interneurons that normally inhibit pyramidal neurons, producing disinhibition and increased (not decreased) pyramidal cell glutamate release. The net effect is a glutamate burst, not a reduction in excitatory signaling.
• Option C: Option C is incorrect because Ketamine's primary mechanism does not involve direct blockade of NMDA receptors on serotonergic neurons or increased serotonin release through an SSRI-like mechanism. The disinhibition model is centered on glutamatergic circuits in the prefrontal cortex. While serotonergic tone may be affected downstream (particularly through lateral habenula effects), this is not the initial mechanistic step.
• Option D: Option D is incorrect because AMPA receptors and NMDA receptors are separate receptor proteins. Ketamine blocks the NMDA receptor channel pore; it does not act directly on AMPA receptors. AMPA receptors are activated downstream by the glutamate burst that results from GABAergic interneuron disinhibition, not by direct ketamine action.
• Option E: Option E is incorrect because While ketamine may affect dopaminergic neurons indirectly, the primary disinhibition mechanism involves GABAergic interneurons in the prefrontal cortex, not dopaminergic neurons in the ventral tegmental area. Dopaminergic effects are more relevant to the lateral habenula pathway and are a downstream consequence rather than the initial mechanistic step.

ANSWER: A

Rationale:

The mammalian target of rapamycin complex 1 (mTORC1) is the critical final effector in the molecular cascade that mediates ketamine's rapid antidepressant effects. Following NMDA blockade, the resulting glutamate burst activates AMPA receptors, which triggers BDNF release and TrkB receptor activation. TrkB signaling activates the PI3K/Akt pathway, which converges on mTORC1. As a master regulator of protein synthesis, mTORC1 activation drives the rapid translation of synaptic proteins including the AMPA receptor subunit GluA1, postsynaptic density protein 95 (PSD-95), and synapsin I. This protein synthesis supports the rapid formation of new dendritic spines and functional synapses in prefrontal cortical pyramidal neurons, a process that occurs within hours and represents the structural correlate of ketamine's antidepressant effect. The causal role of mTORC1 was established by demonstrating that rapamycin, a specific mTORC1 inhibitor, blocks both the synaptogenic and the behavioral antidepressant effects of ketamine in animal models.

• Option B: Option B is incorrect because While MAPK/ERK signaling is involved in neuroplasticity and is activated by neurotrophic factors, it is not the kinase complex whose inhibition by rapamycin specifically blocks ketamine's antidepressant and synaptogenic effects. The rapamycin-sensitive component is mTORC1, not MAPK/ERK.
• Option C: Option C is incorrect because GSK-3beta is a kinase that has been studied in the context of mood disorders and is inhibited by lithium, but it is not the kinase complex whose blockade by rapamycin abolishes ketamine's antidepressant effects. GSK-3beta inhibition may contribute to ketamine's effects through a separate pathway, but mTORC1 is the rapamycin-sensitive effector.
• Option D: Option D is incorrect because CaMKII is an important signaling enzyme in synaptic plasticity and learning, but it is not the kinase complex targeted by rapamycin. The specific abolition of ketamine's effects by rapamycin identifies mTORC1 as the critical downstream effector in the antidepressant cascade.
• Option E: Option E is incorrect because JAK2 is a tyrosine kinase involved in cytokine and growth factor receptor signaling, primarily in immune and hematopoietic cells. It is not a component of the BDNF-TrkB-mTORC1 synaptogenesis pathway that mediates ketamine's rapid antidepressant effects and is not the target of rapamycin.

ANSWER: D

Rationale:

The lateral habenula pathway represents an additional mechanism through which ketamine produces rapid antidepressant effects, particularly in restoring hedonic function and motivation. In animal models of depression, LHb neurons exhibit pathological NMDA receptor-dependent burst firing that suppresses dopamine release in the nucleus accumbens and reduces serotonergic output from the raphe nuclei, producing anhedonia and motivational deficits. Ketamine blocks NMDA receptors on these LHb neurons, suppressing their burst firing and thereby disinhibiting the downstream dopaminergic and serotonergic reward circuits. This mechanism provides a pathway through which ketamine can rapidly restore hedonic function and motivation, features of depression that respond slowly to conventional monoamine-based antidepressants. The LHb mechanism operates independently of the prefrontal cortex disinhibition-synaptogenesis pathway and may explain why ketamine addresses anhedonia specifically, a symptom domain that is often poorly responsive to SSRIs and SNRIs.

• Option A: Option A is incorrect because This reverses the actual mechanism. Ketamine blocks, rather than activates, NMDA receptors on LHb neurons. The therapeutic effect comes from suppressing pathological burst firing, not amplifying it. Increasing burst-firing activity would worsen, not improve, depressive symptoms.
• Option B: Option B is incorrect because Ketamine acts at NMDA receptors, not AMPA receptors. The blockade of NMDA receptors on LHb neurons suppresses their burst-firing activity specifically; it does not work through AMPA receptor blockade.
• Option C: Option C is incorrect because Ketamine does not destroy LHb neurons. Its effect is pharmacological and reversible: NMDA receptor blockade temporarily suppresses burst firing. When ketamine is cleared and NMDA receptors are no longer blocked, LHb neuronal function returns. This reversibility is consistent with the transient nature of ketamine's antidepressant effects.
• Option E: Option E is incorrect because Ketamine's mechanism at the lateral habenula involves NMDA receptor blockade, not serotonin reuptake enhancement. Serotonergic effects downstream of LHb disinhibition occur because reduced LHb firing releases raphe nuclei from inhibition, increasing serotonin output, but this is a downstream consequence of NMDA blockade, not a direct serotonin reuptake mechanism.

ANSWER: C

Rationale:

The absolute bioavailability of intranasal esketamine is approximately 48%, meaning that roughly half of the administered dose reaches the systemic circulation compared with 100% for IV administration (IV bioavailability is 100% by definition because the drug is delivered directly into the bloodstream). The lower bioavailability of the intranasal route results from incomplete absorption through the nasal mucosa and swallowing of a portion of the administered drug, which then undergoes hepatic first-pass metabolism. There is considerable inter-individual variability in nasal absorption related to factors including nasal congestion, mucosal vascularity, and administration technique. Peak plasma concentrations (Tmax) are reached within 20 to 40 minutes of intranasal administration. Despite the lower bioavailability, the intranasal route delivers sufficient systemic esketamine to produce clinically meaningful NMDA receptor occupancy and antidepressant effects at the approved doses of 56 mg or 84 mg.

• Option A: Option A is incorrect because An estimate of 90% substantially overestimates intranasal bioavailability. The nasal mucosa does not provide the highly efficient absorption implied; approximately half the dose is lost to incomplete absorption and first-pass metabolism of the swallowed fraction.
• Option B: Option B is incorrect because An estimate of 10% substantially underestimates intranasal bioavailability. At 10% bioavailability, the approved intranasal doses would be unlikely to achieve the plasma concentrations needed for meaningful NMDA receptor occupancy and antidepressant effect.
• Option D: Option D is incorrect because IV and intranasal routes do not provide identical bioavailability. IV administration delivers 100% of the dose to the systemic circulation, while intranasal delivery provides approximately 48%, a pharmacokinetically significant difference that is reflected in the dose selections for each route.
• Option E: Option E is incorrect because An estimate of 75% overestimates intranasal bioavailability and incorrectly attributes the loss to first-pass metabolism in the nasal mucosa. The bioavailability reduction is primarily due to incomplete mucosal absorption and hepatic first-pass metabolism of the swallowed portion, not nasal mucosal metabolism.

ANSWER: E

Rationale:

Ketamine undergoes hepatic metabolism primarily via the cytochrome P450 enzymes CYP3A4 and CYP2B6 through N-demethylation to produce norketamine, its primary metabolite. Norketamine is pharmacologically active but has weaker NMDA antagonist activity than the parent compound and a longer half-life of approximately five hours compared with ketamine's two to three hours. Norketamine is further metabolized to hydroxynorketamine (HNK), with the metabolite (2R,6R)-hydroxynorketamine receiving particular research attention because it has been shown to produce antidepressant-like effects in animal models without dissociation and without NMDA receptor blockade, possibly through AMPA receptor potentiation. Whether HNK contributes meaningfully to the antidepressant effects of ketamine in humans at the concentrations achieved after standard antidepressant dosing remains an active area of investigation.

• Option A: Option A is incorrect because Ketamine is metabolized primarily by CYP3A4 and CYP2B6, not CYP2D6. The primary metabolite is norketamine (produced by N-demethylation), not desmethylketamine, and norketamine is pharmacologically active, not inactive.
• Option B: Option B is incorrect because Ketamine undergoes Phase I oxidative metabolism (N-demethylation via CYP enzymes) before any Phase II conjugation. It does not undergo direct glucuronidation without prior Phase I metabolism.
• Option C: Option C is incorrect because CYP1A2 is not the primary enzyme responsible for ketamine metabolism. The primary metabolite is norketamine, not hydroxyketamine, and norketamine has NMDA antagonist activity (weaker than the parent), not agonist activity.
• Option D: Option D is incorrect because Ketamine is not cleaved by plasma esterases. Unlike remifentanil, which contains an ester bond hydrolyzed by tissue and plasma esterases, ketamine is metabolized through hepatic cytochrome P450-mediated N-demethylation.

ANSWER: B

Rationale:

Dissociation is a dose-dependent pharmacodynamic effect of ketamine that correlates directly with the degree of NMDA receptor occupancy. At the standard antidepressant dose of 0.5 mg/kg IV infused over 40 minutes, dissociative symptoms begin within minutes of infusion onset, peak near the end of the infusion, and resolve within 60 to 90 minutes after infusion completion in most patients. The dissociative experience at antidepressant doses is characterized by perceptual distortions, derealization, depersonalization, altered sense of time, and occasionally visual or auditory misperceptions that do not reach the intensity of frank psychosis. The Clinician-Administered Dissociative States Scale (CADSS) can be used to formally quantify dissociative intensity. At subanesthetic doses, dissociative symptoms are typically manageable without pharmacological intervention and resolve spontaneously as plasma ketamine concentrations decline.

• Option A: Option A is incorrect because Dissociation is not idiosyncratic. It is a predictable, dose-dependent pharmacological effect that occurs in the majority of patients receiving ketamine at antidepressant doses. Higher doses produce greater dissociation because they achieve higher NMDA receptor occupancy.
• Option C: Option C is incorrect because Dissociation does not persist for 24 to 48 hours. It resolves within 60 to 90 minutes after infusion completion at antidepressant doses, consistent with the rapid decline in plasma ketamine concentrations and decreasing NMDA receptor occupancy. Pharmacological intervention is typically unnecessary for managing dissociation at subanesthetic doses.
• Option D: Option D is incorrect because Dissociation does occur at the 0.5 mg/kg subanesthetic dose. While less intense than the profound dissociation seen at anesthetic doses, subanesthetic dissociation is experienced by the majority of patients and is the primary reason for the two-hour post-dose monitoring requirement.
• Option E: Option E is incorrect because Dissociation is not a delayed-onset effect. It begins within minutes of IV infusion, consistent with ketamine's rapid crossing of the blood-brain barrier and immediate onset of NMDA receptor blockade. The antidepressant effect peaks at approximately 24 hours, well after dissociative symptoms have resolved.

ANSWER: D

Rationale:

The difference in onset between ketamine and SSRIs reflects fundamentally distinct mechanisms of action operating on different timescales. Ketamine's antidepressant effect arises from a rapid molecular cascade triggered by NMDA receptor blockade: disinhibition of prefrontal pyramidal neurons produces a glutamate burst that activates AMPA receptors, leading to BDNF release, TrkB activation, and mTORC1-dependent protein synthesis. This cascade produces measurable increases in synaptic proteins and new dendritic spine formation within hours, constituting rapid synaptogenesis that restores synaptic function in prefrontal circuits. In contrast, SSRIs immediately block serotonin reuptake, but the resulting acute increase in synaptic serotonin is not the therapeutic event itself. Rather, weeks of sustained serotonin elevation are required to produce downstream receptor adaptations (including desensitization of inhibitory 5-HT1A autoreceptors), changes in gene expression, and gradual neuroplasticity changes that ultimately mediate the clinical antidepressant effect. These are fundamentally different biological processes, not faster and slower versions of the same mechanism.

• Option A: Option A is incorrect because Ketamine's shorter half-life does not explain its faster onset. Steady-state concentration is not the relevant concept for ketamine because a single infusion produces the antidepressant effect through a rapid downstream cascade. SSRIs' delayed onset is not due to slow achievement of steady-state plasma levels; it is due to the weeks of receptor adaptation required for their mechanism to produce therapeutic benefit.
• Option B: Option B is incorrect because SSRIs do not work within hours. Their initial pharmacological action (blocking serotonin reuptake) occurs immediately, but the downstream receptor adaptations and neuroplasticity changes that produce the clinical antidepressant effect genuinely require weeks to develop. The delay is mechanistic, not a masking effect of side effects.
• Option C: Option C is incorrect because This is pharmacokinetically inaccurate. IV ketamine enters the systemic circulation and crosses the blood-brain barrier through the bloodstream, not through direct nasal-to-brain absorption (which would apply only to intranasal esketamine, and even that formulation relies primarily on systemic absorption through the nasal mucosa). SSRIs also cross the blood-brain barrier readily after oral absorption. Route of administration does not account for the difference in onset.
• Option E: Option E is incorrect because Ketamine and SSRIs do not produce the same downstream synaptic changes. Ketamine drives rapid mTORC1-dependent synaptogenesis through a glutamatergic cascade, while SSRIs produce gradual changes in monoaminergic receptor sensitivity and downstream gene expression over weeks. These are qualitatively different mechanisms, not quantitative differences in potency.

ANSWER: A

Rationale:

A history of aneurysmal vascular disease is an absolute contraindication to both ketamine and esketamine in the antidepressant setting. Ketamine produces sympathomimetic cardiovascular effects through inhibition of catecholamine reuptake, resulting in transient increases in heart rate, systolic blood pressure (typically 10 to 20 mmHg), and diastolic blood pressure (typically 5 to 15 mmHg) at antidepressant doses. In a patient with an existing vascular aneurysm or arteriovenous malformation, these acute blood pressure elevations pose an unacceptable risk of aneurysm rupture or hemorrhage. Additional absolute contraindications include intracerebral hemorrhage and hypersensitivity to ketamine or esketamine. Uncontrolled or severe hypertension is a relative contraindication requiring pre-treatment optimization before administration can be considered.

• Option B: Option B is incorrect because Mild seasonal allergic rhinitis is not a contraindication to ketamine or esketamine. While nasal congestion may reduce the bioavailability of intranasal esketamine, this is managed through dose adjustment and administration technique. It is not a contraindication to IV ketamine, which bypasses the nasal route entirely.
• Option C: Option C is incorrect because Concurrent use of an SSRI is not a contraindication to ketamine or esketamine. In fact, the esketamine REMS program requires concurrent use of an oral antidepressant, which may include an SSRI. The combination does not produce serotonin syndrome because ketamine's mechanism does not involve direct serotonin reuptake inhibition.
• Option D: Option D is incorrect because Elevated BMI is not a contraindication to ketamine or esketamine therapy. The antidepressant dose of IV ketamine is weight-based (0.5 mg/kg), and standard dosing accommodates patients across a wide range of body weights. Lipophilicity does not produce unsafe accumulation at antidepressant doses and frequencies.
• Option E: Option E is incorrect because Esketamine is approved for patients with treatment-resistant depression (defined as failure of two or more adequate antidepressant trials) and for major depressive disorder with acute suicidal ideation or behavior. There is no requirement to have failed five or more trials, and a history of prior antidepressant response does not contraindicate future ketamine use.

ANSWER: E

Rationale:

The TRANSFORM-2 trial was a randomized, double-blind, active-controlled, multicenter study that compared esketamine nasal spray (56 mg or 84 mg twice weekly) combined with a newly initiated oral antidepressant against placebo nasal spray combined with a newly initiated oral antidepressant in patients with treatment-resistant depression. The trial demonstrated that the esketamine group had significantly greater reduction in Montgomery-Asberg Depression Rating Scale (MADRS) scores than the placebo group, with a statistically significant treatment difference emerging by day 2 of treatment, before any meaningful effect of the oral antidepressant could have developed. This rapid separation from placebo was consistent with the expected pharmacological timeline of NMDA-based antidepressant action and was a central piece of evidence supporting the FDA's approval of esketamine for TRD.

• Option A: Option A is incorrect because TRANSFORM-2 did not test esketamine as monotherapy. It compared esketamine plus a newly initiated oral antidepressant against placebo spray plus a newly initiated oral antidepressant. The study found a significant difference favoring esketamine, not equivalence or no difference.
• Option B: Option B is incorrect because TRANSFORM-2 was not a head-to-head comparison of IV racemic ketamine versus intranasal esketamine. No adequately powered randomized trial has directly compared these two formulations. TRANSFORM-2 compared intranasal esketamine against intranasal placebo, both with concurrent oral antidepressant initiation.
• Option C: Option C is incorrect because TRANSFORM-2 was a double-blind, placebo-controlled trial with an efficacy endpoint, not an open-label safety study. The long-term maintenance study for esketamine was the SUSTAIN-1 trial, which had a different design.
• Option D: Option D is incorrect because TRANSFORM-2 did not compare esketamine against venlafaxine as an active comparator. The comparator arm received placebo nasal spray (not an active nasal comparator) combined with a newly initiated oral antidepressant. The trial demonstrated superiority for esketamine, not equivalence.

ANSWER: C

Rationale:

Active psychotic disorders including schizophrenia and schizoaffective disorder represent a clinical contraindication to ketamine and esketamine because NMDA receptor blockade produces dissociative and psychotomimetic effects that risk precipitating new psychotic episodes or exacerbating existing psychotic symptoms. The pharmacological basis is straightforward: NMDA receptor hypofunction has been implicated in the pathophysiology of schizophrenia (the glutamate hypothesis of schizophrenia), and administering an NMDA antagonist to a patient with a primary psychotic disorder could worsen the existing NMDA receptor dysfunction. At antidepressant doses, ketamine produces perceptual distortions, derealization, and depersonalization that, while typically manageable in patients without psychotic disorders, could destabilize a patient with an underlying vulnerability to psychosis. Psychosis-like symptoms occurring beyond the expected window of NMDA blockade should prompt reassessment, and ketamine should be used with extreme caution or avoided entirely in patients with a personal or family history of primary psychotic disorders.

• Option A: Option A is incorrect because The contraindication is not based on serotonin toxicity. Ketamine does not produce serotonin syndrome through NMDA blockade. The risk is specifically that NMDA antagonism produces psychotomimetic effects that can exacerbate psychotic disorders, not a serotonergic adverse reaction.
• Option B: Option B is incorrect because Esketamine does not inhibit CYP2D6, and the contraindication is not based on a pharmacokinetic drug interaction with antipsychotics. It is based on the pharmacodynamic risk that NMDA blockade produces dissociative and psychotomimetic effects capable of destabilizing psychotic disorders.
• Option D: Option D is incorrect because Ketamine does not directly activate dopamine D2 receptors. Its primary mechanism is NMDA receptor blockade. While ketamine may indirectly affect dopaminergic circuits (notably through lateral habenula disinhibition), it does not act as a dopamine agonist. The contraindication is based on the psychotomimetic effects of NMDA antagonism, not direct dopaminergic stimulation.
• Option E: Option E is incorrect because The contraindication is not based on an excess of NMDA receptors or fatal excitotoxicity. The risk is that NMDA blockade produces psychotomimetic effects that can precipitate or worsen psychotic symptoms in patients with underlying psychotic disorders. This is a clinical risk of symptom exacerbation, not a fatal pharmacotoxic reaction.

ANSWER: B

Rationale:

Ketamine produces sympathomimetic cardiovascular effects through inhibition of catecholamine reuptake at sympathetic nerve terminals. By blocking the reuptake of norepinephrine, ketamine increases norepinephrine concentrations in the synaptic cleft at adrenergic receptors in the heart and vasculature, producing transient increases in heart rate, systolic blood pressure, and diastolic blood pressure. At the standard antidepressant dose of 0.5 mg/kg IV, blood pressure increases of 10 to 20 mmHg systolic and 5 to 15 mmHg diastolic are typical, with changes peaking during the infusion and returning toward baseline within 30 to 60 minutes of completion. This catecholamine reuptake inhibition mechanism is why patients with baseline hypertension, cardiac arrhythmias, or a history of hypertensive emergency require pre-treatment blood pressure optimization and close monitoring during infusion.

• Option A: Option A is incorrect because Ketamine does not produce its cardiovascular effects through direct beta-1 adrenergic receptor stimulation. Its mechanism is indirect, operating through inhibition of catecholamine reuptake rather than direct agonism at adrenergic receptors. This distinguishes it from agents like dobutamine that are direct beta-1 agonists.
• Option C: Option C is incorrect because The cardiovascular effects of ketamine are not primarily due to muscarinic M2 receptor blockade. While ketamine has some anticholinergic properties, the dominant mechanism for its cardiovascular stimulation is catecholamine reuptake inhibition, not parasympathetic withdrawal.
• Option D: Option D is incorrect because Ketamine does not produce peripheral vasodilation as its primary cardiovascular effect. The mechanism is sympathomimetic (increasing norepinephrine at adrenergic receptors), which tends to produce vasoconstriction and direct cardiac stimulation rather than vasodilation with reflex tachycardia.
• Option E: Option E is incorrect because Ketamine blocks NMDA receptors; it does not activate them. The cardiovascular effects are mediated peripherally through catecholamine reuptake inhibition at sympathetic nerve terminals, not through central NMDA receptor activation in the medullary vasomotor center.

ANSWER: A

Rationale:

Ketamine-induced uropathy is a severe bladder condition associated with chronic high-dose recreational ketamine use, not with the controlled doses and limited frequency of administration used in antidepressant treatment protocols. The condition is characterized by interstitial cystitis, inflammatory infiltration and fibrosis of the bladder wall, reduced bladder capacity, frequency and urgency of urination, and in severe cases hydronephrosis and renal damage that may require cystectomy. The pathological process is related to the cumulative exposure of bladder epithelium to ketamine and its metabolites at the high doses and high frequencies of recreational use. At the standard antidepressant dose of 0.5 mg/kg IV administered two to three times weekly or less frequently during maintenance, cumulative bladder exposure is orders of magnitude lower than in recreational contexts. However, clinicians overseeing patients receiving repeated ketamine treatments over extended periods should remain aware of bladder symptoms and inquire about them at regular intervals as a monitoring precaution.

• Option B: Option B is incorrect because Ketamine does not cause irreversible renal tubular necrosis at antidepressant doses. The renal involvement in ketamine-induced uropathy, when it occurs, is secondary to obstructive uropathy from severe bladder disease, not direct renal tubular toxicity. A single antidepressant infusion does not require one year of renal monitoring.
• Option C: Option C is incorrect because Ketamine-induced uropathy is not hemorrhagic cystitis and is not caused by the same mechanism as cyclophosphamide bladder toxicity. Cyclophosphamide produces hemorrhagic cystitis through the toxic metabolite acrolein, which is prevented by mesna. Ketamine uropathy involves a different pathological process (interstitial cystitis with fibrosis) and is not prevented by mesna.
• Option D: Option D is incorrect because Ketamine-induced uropathy is dose and frequency dependent. It is associated with chronic high-dose recreational use, not with the lower doses and controlled frequencies used in antidepressant protocols. The mechanism involves cumulative bladder epithelial exposure, which is dramatically lower at antidepressant dosing.
• Option E: Option E is incorrect because Ketamine-induced uropathy is not benign urinary retention and is not simply an anticholinergic effect. It is a destructive inflammatory and fibrotic bladder condition that can cause permanent structural damage including reduced bladder capacity and hydronephrosis. Describing it as benign and fully reversible seriously mischaracterizes the condition.